Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biohaven Ltd. Common Shares (NY:BHVN)

23.02 +1.60 (+7.47%)
Streaming Delayed Price Updated: 3:02 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biohaven Ltd. Common Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
From Pomerantz LLP
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
From Pomerantz LLP
Via GlobeNewswire
Why Biohaven Stock Triumphed on Tuesday
Via The Motley Fool
What's Going On With Merus Stock Monday?
Merus announced a research collaboration and license agreement with Biohaven. 
Via Benzinga
BHVN Investors Have Opportunity to Join Biohaven Ltd. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
From Pomerantz LLP
Via GlobeNewswire
Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March
Via The Motley Fool
Topics Bankruptcy Economy World Trade
Exposures Economy Financial Legal
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
From Pomerantz LLP
Via GlobeNewswire
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
From Avalo Therapeutics
Via GlobeNewswire
Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity
Analysts remains bullish on the company's chances in depression and epilepsy. But investors aren't convinced. 
Via Investor's Business Daily
Strong Immunoglobulin Reduction Data Positions Biohaven's BHV-1300 As Potential Autoimmune Therapy
Biohaven's BHV-1300 reduced IgG levels by up to 84% in a Phase 1 trial for autoimmune disease, with rapid and sustained effects and a favorable safety profile. 
Via Benzinga
Tesla Rebounds While Tariffs Weigh On Manufacturing: What's Driving Markets Monday?
Stocks fell broadly on Monday to start the month of March with all three major indices red in midday trading. Investors digested a decline in February's ISM Manufacturing PMI data which fell to 50.3%,... 
Via Benzinga
Biohaven Just Hurdled An FDA Setback — And Its Moving Lines
The company could soon add a new, high-value treatment to its portfolio. 
Via Investor's Business Daily
Exposures Product Safety
Financial Crime Weekly: Pfizer Pays Nearly $60 Million To Resolve False Claims Allegations, SEC Creates Crypto Task Force
The DOJ announces Pfizer agreed to pay nearly $60 million to resolve false claims allegations. The SEC creates a task force dedicated to the development of a clear and comprehensive regulatory... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
From Merus N.V.
Via GlobeNewswire
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval
Biohaven's BHV-1300 shows >60% IgG reduction in early trials with promising safety data, advancing its MoDE platform and regulatory milestones. 
Via Benzinga
Archer Aviation, Hims & Hers Health And Urban Outfitters Are Among Top 8 Mid-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?
8 mid-cap stocks saw impressive gains last week. Archer, Scholar Rock, Arrowhead, Iris Energy, Hims & Hers, SoundHound, Joby Aviation, and Urban Outfitters all performed well. 
Via Benzinga
Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study
Biohaven reported taldefgrobep data showing motor function gains in SMA and plans to advance obesity studies with an autoinjector in 4Q24. 
Via Benzinga
Cassava Sciences, Biohaven And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Scholar Rock Catapults By Triple Digits On Final-Phase Win In Spinal Muscular Atrophy
The company is hoping to treat patients with spinal muscular atrophy, a muscle-wasting disease. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Acuity Brands, Nike And 3 Stocks To Watch Heading Into Tuesday
Via Benzinga
Hewlett Packard Enterprise, Nvidia, Progress Software And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
Biohaven, a clinical-stage biopharmaceutical company, is attracting investors with promising results for its experimental drug. 
Via MarketBeat
Dow Gains Over 50 Points; Elevai Labs Shares Plummet
Via Benzinga
Topics Stocks
Exposures US Equities
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.